In Brief: Sanofi
This article was originally published in The Gray Sheet
Sanofi: Launches its Access CK-MB Assay, a two-site immunoenzymatic (sandwich) test that "utilizes paramagnetic particle, chemiluminescent technology to determine CK-MB levels in human serum or plasma EDTA." The assay will be sold in packages of 100 determinations. Each package will carry a list price of $650, the company says. "The development and commercialization of our Access CK-MB assay represents Sanofi Diagnostic Pasteur, Inc.'s commitment to providing a full cardiac menu on the Access System," the company says, noting that it plans to launch Access assays for Myoglobin and Troponin I in 1996...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.